Table 3.
Ongoing cardiovascular outcomes trials of GLP1-RAs
| Agent | Company | Development stage | Indication | ClinicalTrials.gov ID |
|---|---|---|---|---|
| GLP1/glucagon dual agonists | ||||
| Cotadutide | AstraZeneca | Phase III | NASH |
(active, not recruiting) |
| Survodutide | Boehringer Ingelheim | Phase III | Obesity | NCT06066515 (recruiting) |
| Efinopegdutide | MSD | Phase II | NASH | NCT05877547 (recruiting) |
| Mazdutide | Eli Lilly | Phase III | Obesity |
(active, not recruiting) |
| DA-1726 | NeuroBo Pharmaceuticals | Phase I | Obesity |
(not yet recruiting) |
| GIP/GLP1 dual agonists | ||||
| Tirzepatide | Eli Lilly | Phase II | NASH |
(active, not recruiting) |
| NN9709 | Novo Nordisk | Discontinued | Obesity, T2D | NCT02205528 (completed) |
| GIP/GLP1/glucagon tri-agonists | ||||
| HM15211 | Hanmi Pharmaceutical | Phase II | NASH | NCT04505436 (recruiting) |
| Retatrutide | Eli Lilly | Phase III | Obesity | NCT05882045 (recruiting) |
| NN9423 | Novo Nordisk | Discontinued | Obesity, T2D | NCT03661879 (completed) |
| GLP1R agonists | ||||
| Efpeglenatide | Hanmi Pharmaceutical | Phase III | T2D | NCT03353350 (completed) NCT03496298 (terminated) |
| Phase II | NASH | NCT04505436 (recruiting) | ||
| Danuglipron | Pfizer | Phase II | Obesity | NCT04707313 (completed) |
| Phase II | T2D | NCT03985293 (completed) | ||
| Orforglipron | Eli Lilly | Phase III | T2D | NCT05872620 (recruiting) |
| Obesity | NCT05869903 (recruiting) | |||
| Lotiglipron | Pfizer | withdrawn | ||